Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Semaglutide

STEP 1

Novo Nordisk · Phase 3 · Completed · Enrollment 1961

NCT03548935

Y axis: Change in body weight from baseline, %

0-5-10-150481216202436486072Semaglutide s.c. 2.4 mg once weekly, week 68, -14.9%Semaglutide s.c. 2.4 mg once weeklySemaglutide placebo, week 68, -2.4%Semaglutide placebo

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

  • Semaglutide s.c. 2.4 mg once weekly: week 68 -14.9%
  • Semaglutide placebo: week 68 -2.4%

One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.